Yangxue Qingnao pill
PreclinicalSmall molecule
Yangxue Qingnao pill is one of 65 small molecule programs targeting Headache Disorder. It is currently in Preclinical.
3
Indications
3
Total Trials
1
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
72 competitors in Cognitive Impairment
#DrugCompanyPhaseTrials
1Ritalin
NovartisApproved
Azilect
TevaApproved
Marinol
Jazz PharmaceuticalsApproved
Brintellix
TakedaApproved
Intropin
PfizerApproved
Lithobid
SSolvay Pharmaceuticals
Approved
Bendopa
MMerz North America, Inc.
Approved
Lamictal
GGlaxo Dba Glaxosmithkline
Approved
Nimotop
AAzurity Pharmaceuticals
Approved
Targretin
BBausch Health Americas, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cerebral Infarction1 trial
Cognitive impairment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Yangxue Qingnao pill. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPeking University Third Hospital